Tag : ACUTE MYELOID LEUKEMIA

CONFERENCE UPDATE

Post-HSCT gilteritinib resumption improves OS in R/R FLT3mut+ AML: Pooled analysis of the phase 3 ADMIRAL and COMMODORE trials
Gilteritinib resumption post-hematopoietic stem cell transplantation (HSCT) improved overall survival (OS) in relapsed/refractory FMS-like tyrosine kinase 3-mutated acute myeloid leukemia (R/R FLT3mut+ AML) in a pooled analysis of ADMIRAL and COMMODORE, with landmark data suggesting reduced relapse or death in relapse-free day-60 HSCT patients.
CONFERENCE UPDATE

Gilteritinib continues to improve OS in R/R FLT3-mutated AML at 3-year follow-up of the Asian-centric phase 3 COMMODORE trial
Relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) is associated with a poor prognosis.1 While global trials have demonstrated that gilteritinib offers superior survival benefits and a favorable safety profile compared to standard chemotherapy, long-term randomized
NEWS AND PERSPECTIVE

PLK4 inhibition as a promising therapeutic target for TP53-mutated AML
Abnormalities in the tumor protein 53 (TP53) gene occur in approximately 5%-10% of patients with de novo acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Despite 4 decades of research, the prognosis of patients with TP53-mutated (TP53mut) cancers remains poor as they often respond poorly to cytotoxic chemotherapy. These patients may have a median survival of 5 to 10 months, irrespective of therapies used. In a recent study, researchers from the University of Hong Kong’s Faculty of Medicine (HKUMed) identified the therapeutic potential of pololike kinase 4 (PLK4) inhibition in AML and the possible mechanisms behind its in vivo efficacy.